Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

Phase 2 Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

To determine the activity and response rate of AG-013736 in patients with advanced and refractory renal cell cancer, (patients who also failed on sorafenib-based therapy).

Inclusion Criteria:

• RCC with metastases and nephrectomy
• failure of prior sorafenib-based therapy
• at least 1 target lesion that has not been irradiated
• adequate bone marrow, hepatic and renal function, > or equal to 18 years of age.

Exclusion Criteria:

• Gastrointestinal abnormalities
• current use or inability to avoid chronic antacid therapy
• current use or anticipated inability to avoid potent CYP3A4 inhibitors or CYP1A2 inducers
• active seizure disorder or evidence of brain metastases.